Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
September 2015
-
Media Release
Novartis lance « Novartis Access », une gamme de médicaments à prix abordables pour lutter contre les maladies chroniques dans les pays à faible revenu
Une approche unique en son genre dans l'industrie de la santé, qui vise à rendre 15 médicaments plus facilement disponibles et plus accessibles pour traiter les maladies cardiovasculaires, le diabète… -
Media Release
Novartis lanciert "Novartis Access", ein Portfolio von erschwinglichen Medikamenten zur Behandlung von chronischen Erkrankungen in Ländern mit niedrigen Einkommen
Neuartiger Portfolioansatz in der Gesundheitsbranche mit dem Ziel, die Verfügbarkeit und Erschwinglichkeit von 15 Medikamenten gegen Herz-Kreislauf-Erkrankungen, Diabetes, Atemwegserkrankungen und… -
Media Release
Swissmedic approves Novartis' new heart failure medicine Entresto(TM)
Decision by Swiss Health Authority follows US Food and Drug Administration (FDA) approval of Entresto in July, serves as an important reference approval for multiple other health authorities… -
Media Release
Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
Telemedicine pilot in rural Ghana demonstrated positive impact and improved primary health services as reported by nurses, midwives and patients Retrospective contact tracing of former leprosy… -
Media Release
Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma
Farydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak… -
Media Release
Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States
Launch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here: Holzkirchen,… -
Media Release
Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia
Revolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder,… -
Media Release
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan… -
Media Release
Novartis setzt sich weiter für die endgültige Ausrottung von Lepra ein
Die Vereinbarung für die kommenden fünf Jahre umfasst Spenden von Behandlungseinheiten im Wert von mehr als USD 40 Millionen, mit denen rund 1,3 Millionen Patienten geholfen werden… -
Media Release
Novartis renouvelle son engagement à l'approche de la dernière ligne droite dans la lutte visant à éradiquer la lèpre
Ce nouvel engagement sur cinq ans comprend un don de médicaments d'une valeur estimée à plus d'USD 40 millions qui devrait permettre de traiter environ 1,3 million de patients Le nouveau… -
Media Release
Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form of melanoma
Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy Targeted combination offers…